We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Mobile Heart-Lung Machine Improves Heart Attack Survival

By HospiMedica International staff writers
Posted on 13 Aug 2021
An advance mobile system for personalized control of extracorporeal circulation helps preserve brain function during resuscitation following cardiac arrest. More...


The Resuscitec (Freiburg, Germany) CARL system is designed to perform controlled automated reperfusion of the whole body in order to improve survival and neurologic recovery in patients affected by acute cardiac arrest. The system includes three main elements:
  • CARL.CONTROLLER, a perfusion system with powerful, automated dual pump control to generate high pulsatile blood flow, a comprehensive measurement sensor system with online venous and arterial blood gas analysis and plug-in fibre optic catheter for invasive blood pressure monitoring, and a preconfigured, compact perfusion set for quick and easy system start-up.
  • CARL. MOX, A mobile oxygen supply for controlled oxygenation and decarboxylation in the extracorporeal circuit. The resource-saving system makes use of room air by means of blower technology, precisely controlling O2 concentration (21 to 100%) and CO2 elimination (up to 12 l/min gas flow). The system can run for approximately four hours on battery power.
  • The CARL.COOLER, a mobile hypothermia device for rapid therapeutic cooling in the context of extracorporeal circulation, which can provide up to 4 °C cooling capacity within a few minutes. A disposable cooler kit provides resource-independent cooling by endothermic reaction, with direct connection to the oxygenator.
The technological performance characteristics of the CARL System components are based on the requirements of CARL Therapy, a novel therapeutic approach for resuscitation that emphasizes controlled, targeted, and personalized whole-body reperfusion. The unique, dual-pump control system enables the powerful pulsatile blood flow necessary for maintaining high blood pressure, precise control of oxygen levels, and rapid, safe cooling of body temperature.

“Oxygen levels must be low and increased only slowly. Otherwise, free radicals are generated in the tissues. These very aggressive molecules can then attack, among other things, the mitochondria, the power plants of the cells,” said Professor Friedhelm Beyersdorf, MD, of the University of Freiburg, co-developer of CARL. “The CARL method incorporates the latest basic research and state-of-the-art cardiac techniques. After decades of research, we were able to develop a new treatment method to reduce the physical damage that would otherwise occur after cardiac arrest and resuscitation.”

Related Links:

Resuscitec

Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: A UTSW clinical trial studied a treatment strategy for kidney cancer with inferior vena cava tumor thrombus (IVC-TT) that used targeted radiation on the tumor thrombus followed by surgery to remove the kidney. (Photo courtesy of UT Southwestern)

Targeted Radiotherapy Before Surgery Improves Control of Kidney Cancer Thrombus

Inferior vena cava tumor thrombus occurs when kidney cancer extends into the body’s largest vein, potentially obstructing blood flow, progressing toward the heart, and making surgery more complex.... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Brain PET imaging could help identify Alzheimer’s patients most likely to benefit from available therapies (Image Credit: iStock)

Amyloid and Tau PET Guide Selection and Monitoring of Alzheimer’s Therapy

Alzheimer’s disease is the most common form of dementia and can be difficult to distinguish from other causes of cognitive decline. According to the World Health Organization (WHO), 57 million people were... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.